On ECHEMI
Home > Drugs > stillbirth
stillbirth
After 20 weeks of pregnancy, the fetus dies in utero, which is about one in every two hundred pregnancy cases. (The death of the fetus during delivery is called stillbirth, which is also a type of stillbirth.) Since about half of the cases of stillbirth have no signs of problems during pregnancy, most parents lose their fetuses without realizing it. When fetal movement suddenly stops, pregnant women may suspect that something is wrong. More than half of stillbirths are caused by fetal hypoxia. The causes of hypoxia include placental factors such as placenta previa, early placental detachment, umbilical cord prolapse, umbilical cord knotting, and umbilical cord around the neck affecting blood supply; fetal factors such as multiple births, intrauterine growth retardation, and teratoma; maternal factors such as pregnancy-induced hypertension syndrome, diabetes, and overdue pregnancy; local uterine factors such as excessive uterine tension or strong contraction, uterine rupture, etc. After the fetus dies, the pregnant woman feels that the fetal movement has stopped, the breast swelling disappears, the uterus no longer continues to grow, the weight decreases, and the fetal heart disappears, then the possibility of stillbirth can be considered. B-type ultrasound examination indicates that the fetal movement and fetal heart disappear, and sometimes the fetal head has been deformed, which can be confirmed. Most dead fetuses can be expelled on their own. If they are not expelled within 3 weeks after death, the degenerated placenta and amniotic fluid will release thromboplastin into the maternal blood circulation, causing disseminated intravascular coagulation (DIC).
  • Site of disease:

    Uterus
  • Infectious :

    Not contagious
  • Frequent population:

    Pregnant women
  • Related symptoms:

    Fetal intrauterine asphyxia weight loss disappearance of fetal heartbeat (no fetal heartbeat) reduced fetal movement fatigue
  • Concurrent disease:

Related Drugs
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product is better than other antifibrinolytic drugs in stopping bleeding, but
Manufacturer:

Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd.

Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:

Hubei Jinyao Pharmaceutical Co., Ltd.

Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product is superior to other anti-fibrotic drugs in stopping bleeding.
Manufacturer:

Chongqing Lummy Pharmaceutical Co., Ltd.

Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. This product is generally not used for secondary hyperfibrinolytic state caused by disseminated intravascular coagulation before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. This product is better than other antifibrinolytic drugs for hemostasis, but
Manufacturer:

Chongqing Lummy Pharmaceutical Co., Ltd.

Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Compound bovine fetal liver extract tablets
Indication: Used as an auxiliary treatment for acute and chronic hepatitis, liver fibrosis, fatty liver, cirrhosis, etc.
Manufacturer:

Beijing No.1 Biochemical Pharmaceutical Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Changzhou Yinsheng Pharmaceutical Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Hainan Huluwa Pharmaceutical Group Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.